Cortactin in breast cancer: Analysis with tissue microarray

Shyr Ming Sheen-Chen, Chun Ying Huang, Yu Yin Liu, Chao Cheng Huang, Rei Ping Tang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Tissue microarray (TMA) allows the rapid immunohistochemical analysis of thousands of tissue samples in a parallel fashion. This study was designed to analyze the cortactin status in breast cancer using TMA and to investigate the relationship of cortactin status to breast cancer biology. Patients and Methods: Archival tissue specimens from 99 patients with primary invasive breast cancer were selected. The cortactin expression was analyzed by TMA. Age, estrogen receptor status, histological grading and TNM staging data were also collected. Results: There were 23 patients (23.2%) with low (+) expression of cortactin, 60 patients (60.6%) with intermediate (++) expression and 16(16.2%) with strong (+++) expression. There was no significant relationship between cortactin expression and age, histological grading, primary tumor staging, lymph node status, estrogen receptor and TNM stage. By multivariate analysis, estrogen receptor status and TNM staging were found to be significantly related to the overall five-year survival rate. Conclusion: Cortactin expression failed to demonstrate a prognostic value for patients with breast cancer.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalAnticancer Research
Volume31
Issue number1
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Cortactin
Tissue Array Analysis
Breast Neoplasms
Neoplasm Staging
Estrogen Receptors
Multivariate Analysis
Survival Rate
Lymph Nodes

Keywords

  • Breast cancer
  • Cortactin
  • Tissue microarray

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sheen-Chen, S. M., Huang, C. Y., Liu, Y. Y., Huang, C. C., & Tang, R. P. (2011). Cortactin in breast cancer: Analysis with tissue microarray. Anticancer Research, 31(1), 293-297.

Cortactin in breast cancer : Analysis with tissue microarray. / Sheen-Chen, Shyr Ming; Huang, Chun Ying; Liu, Yu Yin; Huang, Chao Cheng; Tang, Rei Ping.

In: Anticancer Research, Vol. 31, No. 1, 01.01.2011, p. 293-297.

Research output: Contribution to journalArticle

Sheen-Chen, SM, Huang, CY, Liu, YY, Huang, CC & Tang, RP 2011, 'Cortactin in breast cancer: Analysis with tissue microarray', Anticancer Research, vol. 31, no. 1, pp. 293-297.
Sheen-Chen SM, Huang CY, Liu YY, Huang CC, Tang RP. Cortactin in breast cancer: Analysis with tissue microarray. Anticancer Research. 2011 Jan 1;31(1):293-297.
Sheen-Chen, Shyr Ming ; Huang, Chun Ying ; Liu, Yu Yin ; Huang, Chao Cheng ; Tang, Rei Ping. / Cortactin in breast cancer : Analysis with tissue microarray. In: Anticancer Research. 2011 ; Vol. 31, No. 1. pp. 293-297.
@article{afc04a7072ef4e05b79093e58d6ac966,
title = "Cortactin in breast cancer: Analysis with tissue microarray",
abstract = "Background: Tissue microarray (TMA) allows the rapid immunohistochemical analysis of thousands of tissue samples in a parallel fashion. This study was designed to analyze the cortactin status in breast cancer using TMA and to investigate the relationship of cortactin status to breast cancer biology. Patients and Methods: Archival tissue specimens from 99 patients with primary invasive breast cancer were selected. The cortactin expression was analyzed by TMA. Age, estrogen receptor status, histological grading and TNM staging data were also collected. Results: There were 23 patients (23.2{\%}) with low (+) expression of cortactin, 60 patients (60.6{\%}) with intermediate (++) expression and 16(16.2{\%}) with strong (+++) expression. There was no significant relationship between cortactin expression and age, histological grading, primary tumor staging, lymph node status, estrogen receptor and TNM stage. By multivariate analysis, estrogen receptor status and TNM staging were found to be significantly related to the overall five-year survival rate. Conclusion: Cortactin expression failed to demonstrate a prognostic value for patients with breast cancer.",
keywords = "Breast cancer, Cortactin, Tissue microarray",
author = "Sheen-Chen, {Shyr Ming} and Huang, {Chun Ying} and Liu, {Yu Yin} and Huang, {Chao Cheng} and Tang, {Rei Ping}",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "293--297",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Cortactin in breast cancer

T2 - Analysis with tissue microarray

AU - Sheen-Chen, Shyr Ming

AU - Huang, Chun Ying

AU - Liu, Yu Yin

AU - Huang, Chao Cheng

AU - Tang, Rei Ping

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Tissue microarray (TMA) allows the rapid immunohistochemical analysis of thousands of tissue samples in a parallel fashion. This study was designed to analyze the cortactin status in breast cancer using TMA and to investigate the relationship of cortactin status to breast cancer biology. Patients and Methods: Archival tissue specimens from 99 patients with primary invasive breast cancer were selected. The cortactin expression was analyzed by TMA. Age, estrogen receptor status, histological grading and TNM staging data were also collected. Results: There were 23 patients (23.2%) with low (+) expression of cortactin, 60 patients (60.6%) with intermediate (++) expression and 16(16.2%) with strong (+++) expression. There was no significant relationship between cortactin expression and age, histological grading, primary tumor staging, lymph node status, estrogen receptor and TNM stage. By multivariate analysis, estrogen receptor status and TNM staging were found to be significantly related to the overall five-year survival rate. Conclusion: Cortactin expression failed to demonstrate a prognostic value for patients with breast cancer.

AB - Background: Tissue microarray (TMA) allows the rapid immunohistochemical analysis of thousands of tissue samples in a parallel fashion. This study was designed to analyze the cortactin status in breast cancer using TMA and to investigate the relationship of cortactin status to breast cancer biology. Patients and Methods: Archival tissue specimens from 99 patients with primary invasive breast cancer were selected. The cortactin expression was analyzed by TMA. Age, estrogen receptor status, histological grading and TNM staging data were also collected. Results: There were 23 patients (23.2%) with low (+) expression of cortactin, 60 patients (60.6%) with intermediate (++) expression and 16(16.2%) with strong (+++) expression. There was no significant relationship between cortactin expression and age, histological grading, primary tumor staging, lymph node status, estrogen receptor and TNM stage. By multivariate analysis, estrogen receptor status and TNM staging were found to be significantly related to the overall five-year survival rate. Conclusion: Cortactin expression failed to demonstrate a prognostic value for patients with breast cancer.

KW - Breast cancer

KW - Cortactin

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=79851499472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851499472&partnerID=8YFLogxK

M3 - Article

C2 - 21273613

AN - SCOPUS:79851499472

VL - 31

SP - 293

EP - 297

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -